Revolution Medicines Inc

RVMD remains in a Stage 2 advancing regime with a clear secular uptrend. Price has pulled back into the rising 9/21 EMA cluster and is holding above the 50 DMA, offering a shallow retracement entry under the Momentum + EPS strategy, so we buy now into the EMA support zone.

• ↑Draxon RASID received breakthrough therapy designation for pancreatic cancer
• ↑Q1 2026 cash and investments of $1.9 B support ongoing R&D and trials
• ↓Q1 2026 net loss of $453.8 M, up from $213.4 M year-over-year